A Phase 1, Randomized, Double-blind, Placebo-controlled, Multiple-dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ALKS 9072 in Subjects With Chronic Stable Schizophrenia.
Phase of Trial: Phase I
Latest Information Update: 07 Oct 2014
At a glance
- Drugs Aripiprazole lauroxil (Primary)
- Indications Schizophrenia
- Focus Pharmacokinetics
- Sponsors Alkermes plc
- 01 Jun 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 08 Feb 2012 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
- 17 Dec 2011 New trial record